Ongoing trials
| Clinical Study | Principal Investigator |
|---|---|
|
Protocol No: CBTL719CIN01
ALPelisib INdia Safety STudy (ALPINIST) : A Phase IV, prospective, multicenter, open-label, non-comparative, interventional study to assess the safety of alpelisib plus fulvestrant, in men and post-menopausal women with HR- positive, HER2-negative, advanced or metastatic Breast Cancer (ABC or MBC) with a PIK3CA mutation, whose disease has progressed on or after endocrine based treatment. |
Dr. Praveena Voonna
|
|
Protocol No: BIO-PERTUZ-301_HAB98922
A Multicenter, Double-Blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients with Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2(HER2)‑positive Early Stage or Locally Advanced Breast Cancer. |
Dr. Praveena Voonna |
|
Protocol No: NAT2694P2
A Phase II Clinical Study to evaluate the efficacy and safety of NRC-2694-A in patients with recurrent Head and Neck Squamous Cell Carcinoma. |
Dr. Rajani Priya Yedla |
|
Protocol No. 0063-17
Study Title: A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy. |
Dr. Praveena Voonna
|
|
Protocol No. NU-01-001
Study Title: A phase I/III, randomised, double blind, multicentre, parallel arm, clinical study comparing the efficacy, safety, immunogenicity and pharmacokinetics of proposed biosimilar nivolumab (DRL_NU) with nivolumab reference medicinal product (OPDIVO®) administered by the intravenous route in patients previously treated for locally advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). |
Dr. Murali Krishna Voonna
|
|
Protocol No: J2J-MC-JZLH
Study Title: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence. |
Dr. Rajani Priya Yedla |
